MedTrace Logo

Multi-Modal Longevity Protocol Including Autologous Cell-Free Conditioned Media

NCT07322224 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-01-07

No results posted yet for this study

Summary

This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.

Conditions

  • Biological Aging
  • Healthy Aging
  • Longevity

Interventions

BEHAVIORAL

Multi-Modal Longevity Protocol

The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.

Sponsors & Collaborators

  • xLongevity

    collaborator UNKNOWN

  • Wellbeing International Foundation

    collaborator UNKNOWN

  • BlueBird Age Reversal SA

    lead INDUSTRY

Principal Investigators

  • Esteban Ortega, MD · Wellbeing International Foundation

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2024-12-15
Completion
2025-03-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07322224 on ClinicalTrials.gov